Paraneoplastic autoimmune multiorgan syndrome: Review of the literature and support for a cytotoxic role in pathogenesis

References

• Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus: An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729–1735
   PubMed Web of Science ®Google Scholar
• Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340: 1406–1410
   PubMed Web of Science ®Google Scholar
• Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147: 725–732
   PubMedGoogle Scholar
• Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993; 129: 883–886
   PubMedGoogle Scholar
• Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: A reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001; 137: 193–206
   PubMedGoogle Scholar
• Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9: 29–33
   PubMedGoogle Scholar
• Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: A review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004; 40: 553–562
   PubMedGoogle Scholar
• Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000; 43: 619–626
   PubMed Web of Science ®Google Scholar
• Camisa C, Helm TN, Liu YC, Valenzuela R, Allen C, Bona S, et al. Paraneoplastic pemphigus: A report of three cases including one long-term survivor. J Am Acad Dermatol 1992; 27: 547–553
   PubMed Web of Science ®Google Scholar
• Inaoki M, Kodera M, Fujimoto A, Nousari HC, Anhalt GJ, Takehara K. Paraneoplastic pemphigus without antidesmoglein 3 or antidesmoglein 1 autoantibodies. Br J Dermatol 2001; 144: 610–613
   PubMedGoogle Scholar
• Leyn J, Degreef H. Paraneoplastic pemphigus in a patient with a thymoma. Dermatology 2001; 202: 151–154
   PubMedGoogle Scholar
• Perera GK, Devereux S, Mufti G, Salisbury J, Creamer D. PNP with Waldenström's macroglobulinaemia. Clin Exp Dermatol 2005; 30: 27–29
   PubMedGoogle Scholar
• Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1995; 132: 474–478
   PubMed Web of Science ®Google Scholar
• Becker LR, Bastian BC, Wesselmann U, Karl S, Hamm H, Brocker EB. Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur J Dermatol 1998; 8: 551–553
   PubMedGoogle Scholar
• Dega H, Laporte JL, Joly P, Gabarre J, Andre C, Delpech A, et al. Paraneoplastic pemphigus associated with Hodgkin's disease. Br J Dermatol 1998; 138: 196–198
   PubMedGoogle Scholar
• Matz H, Milner Y, Frusic-Zlotkin M, Brenner S. Paraneoplastic pemphigus associated with pancreatic carcinoma. Acta Derm Venereol 1997; 77: 289–291
   PubMedGoogle Scholar
• Chamberland M. Paraneoplastic pemphigus and adenocarcinoma of the colon (French). Union Med Can 1993; 122: 201–203
   PubMedGoogle Scholar
• Bowen GM, Peters NT, Fivenson DP, Su LD, Nousari HC, Anhalt GJ, et al. Lichenoid dermatitis in paraneoplastic pemphigus: A pathogenic trigger of epitope spreading?. Arch Dermatol 2000; 136: 652–656
   PubMedGoogle Scholar
• Hinterhuber G, Drach J, Riedl E, Bohler K, Ferenci P, Wolff K, et al. Paraneoplastic pemphigus in association with hepatocellular carcinoma. J Am Acad Dermatol 2003; 49: 538–540
   PubMed Web of Science ®Google Scholar
• Niimi Y, Kawana S, Hashimoto T, Kusunoki T. Paraneoplastic pemphigus associated with uterine carcinoma. J Am Acad Dermatol 2003; 48(5 suppl)S69–S72
   Google Scholar
• Wong KC, Ho KK. Pemphigus with pemphigoid-like presentation, associated with squamous cell carcinoma of the tongue. Australas J Dermatol 2000; 41: 178–180
   PubMedGoogle Scholar
• Aessopos A, Grapsa A, Farmakis D, Sideris P, Politou M, Paikos S, et al. Oral paraneoplastic pemphigus associated with renal malignancy. Acta Derm Venereol 2003; 83: 72–73
   PubMedGoogle Scholar
• Krunic AL, Kokai D, Bacetic B, Kesic V, Nikolic MM, Petkovic S, et al. Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption. Int J Dermatol 1997; 36: 526–529
   PubMedGoogle Scholar
• van der Waal RI, Pas HH, Nousari HC, Schulten EA, Jonkman MF, Nieboer C, et al. Paraneoplastic pemphigus caused by an epithelioid leiomyosarcoma and associated with fatal respiratory failure. Oral Oncol 2000; 36: 390–393
   PubMedGoogle Scholar
• Beele H, Claerhout I, Kestelyn P, Dierckxens L, Naeyaert JM, De Laey JJ. Bilateral corneal melting in a patient with paraneoplastic pemphigus. Dermatology 2001; 202: 147–150
   PubMed Web of Science ®Google Scholar
• Santi CG, Flores RS, Medina MM, Maruta CW, Aoki V, Anhalt G, et al. Paraneoplastic pemphigus associated with pelvic inflammatory fibrosarcoma: A case report. J Dermatol 2005; 32: 1014–1020
   PubMedGoogle Scholar
• Wang J, Bu DF, Li T, Zheng R, Zhang BX, Chen XX, et al. Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br J Dermatol 2005; 153: 558–564
   PubMedGoogle Scholar
• De Saint Paul G, Albes B, Bayle P, Lamant L, Bazex J. Cutaneous T-cell lymphoma, cutaneous hyperpigmentation and paraneoplastic pemphigus (French). Ann Dermatol Venereol 2002; 129: 896–900
   PubMed Web of Science ®Google Scholar
• Schaeppi H, Bauer JW, Hametner R, Metze D, Ortiz-Urda S, Salmhofer W, et al. A localized variant of paraneoplastic pemphigus: Acantholysis associated with malignant melanoma. Br J Dermatol 2001; 144: 1249–1254
   PubMedGoogle Scholar
• Anhalt GJ. Paraneoplastic pemphigus: The role of tumours and drugs. Br J Dermatol 2001; 144: 1102–1104
   PubMedGoogle Scholar
• Ostezan LB, Fabre VC, Caughman SW, Swerlick RA, Korman NJ, Callen JP. Paraneoplastic pemphigus in the absence of a known neoplasm. J Am Acad Dermatol 1995; 33: 312–315
   PubMedGoogle Scholar
• Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol 1992; 128: 1091–1095
   PubMed Web of Science ®Google Scholar
• Gooptu C, Littlewood TJ, Frith P, Lyon CC, Carmichael AJ, Oliwiecki S, et al. Paraneoplastic pemphigus: An association with fludarabine?. Br J Dermatol 2001; 144: 1255–1261
   PubMed Web of Science ®Google Scholar
• Reich K, Brinck U, Letschert M, Blaschke V, Dames K, Braess J, et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol 1999; 141: 739–746
   PubMedGoogle Scholar
• Preisz K, Horvath A, Sardy M, Somlai B, Harsing J, Amagai M, et al. Exacerbation of paraneoplastic pemphigus by cyclophosphamide treatment: Detection of novel autoantigens and bronchial autoantibodies. Br J Dermatol 2004; 150: 1018–1024
   PubMedGoogle Scholar
• Wade MS, Black MM. Paraneoplastic pemphigus: A brief update. Australas J Dermatol 2005; 46: 1–8
   PubMedGoogle Scholar
• Kimyai-Asadi A, Jih MH. Paraneoplastic pemphigus. Int J Dermatol 2001; 40: 367–372
   PubMedGoogle Scholar
• Williams JV, Marks JG, Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506–508
   PubMed Web of Science ®Google Scholar
• Rivollier C, Vaillant L, Machet MC, Martin L, Jan V, Huttenberger B, et al. Paraneoplastic pemphigus: A pustular form during chronic lymphoid leukemia (French). Ann Dermatol Venereol 2001; 128: 644–648
   PubMedGoogle Scholar
• Chorzelski T, Hashimoto T, Maciejewska B, Amagai M, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. J Am Acad Dermatol 1999; 41: 393–400
   PubMedGoogle Scholar
• Zuo YG, Wang BX, Ma DL, Cao BQ, Zhao JH, Guo Y. Mechanism of alopecia in patients with paraneoplastic pemphigus (Chinese). Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27: 354–356
   PubMedGoogle Scholar
• Ng PP, Ng SK, Chng HH. Pemphigus foliaceus and oral lichen planus in a patient with systemic lupus erythematosus and thymoma. Clin Exp Dermatol 1998; 23: 181–184
   PubMedGoogle Scholar
• Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus. J Am Acad Dermatol 2001; 44: 593–598
   PubMed Web of Science ®Google Scholar
• Lane JE, Woody C, Davis LS, Guill MF, Jerath RS. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: Case report and review of the literature. Pediatrics 2004; 114: e513–e516
   PubMedGoogle Scholar
• Mahler V, Antoni C, Anhalt GJ, Koch HJ, Peters KP, Manger B, et al. Graft-versus-host-like mucocutaneous eruptions with serological features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin's lymphoma. Dermatology 1998; 197: 78–83
   PubMedGoogle Scholar
• Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995; 32: 441–447
   PubMedGoogle Scholar
• Liu AY, Valenzuela R, Helm TN, Camisa C, Melton AL, Bergfeld WF. Indirect immunofluorescence on rat bladder transitional epithelium: A test with high specificity for paraneoplastic pemphigus. J Am Acad Dermatol 1993; 28: 696–699
   PubMedGoogle Scholar
• Kanitakis J, Wang YZ, Roche P, Cozzani E, Nicolas JF, Sarret Y, et al. Immunohistopathological study of autoimmune pemphigus: Lack of strictly specific histological and indirect immunofluorescence criteria for paraneoplastic pemphigus. Dermatology 1994; 188: 282–285
   PubMedGoogle Scholar
• Kiyokawa C. Envoplakin and periplakin are the paraneoplastic pemphigus antigens. Kurume Med J 1999; 46: 71–78
   PubMedGoogle Scholar
• Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol 1998; 111: 308–313
   PubMedGoogle Scholar
• Hashimoto T. Immunopathology of paraneoplastic pemphigus. Clin Dermatol 2001; 19: 675–682
   PubMedGoogle Scholar
• Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998; 102: 775–782
   PubMed Web of Science ®Google Scholar
• Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103: 461–468
   PubMed Web of Science ®Google Scholar
• Mimouni D, Foedinger D, Kouba DJ, Orlow SJ, Rappersberger K, Sciubba JJ, et al. Mucosal dominant pemphigus vulgaris with anti-desmoplakin autoantibodies. J Am Acad Dermatol 2004; 51: 62–67
   PubMed Web of Science ®Google Scholar
• Foedinger D, Sterniczky B, Elbe A, Anhalt G, Wolff K, Rappersberger K. Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. J Invest Dermatol 1996; 106: 1012–1016
   PubMedGoogle Scholar
• Nishimura H, Strominger JL. Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. Proc Natl Acad Sci USA 2006; 103: 3292–3297, Feb 28; Epub 2006 Feb 21
   PubMed Web of Science ®Google Scholar
• Elmore SA, Basseches J, Anhalt GJ, Cullen JM, Olivry T. Paraneoplastic pemphigus in a dog with splenic sarcoma. Vet Pathol 2005; 42: 88–91
   PubMedGoogle Scholar
• Williams MA, Dowling PM, Angarano DW, Yu AA, DiFranco BJ, Lenz SD, et al. Paraneoplastic bullous stomatitis in a horse. J Am Vet Med Assoc 1995; 207: 331–334
   PubMedGoogle Scholar
• de Bruin A, Muller E, Wyder M, Anhalt GJ, Lemmens P, Suter MM. Periplakin and envoplakin are target antigens in canine and human paraneoplastic pemphigus. J Am Acad Dermatol 1999; 40: 682–685
   PubMedGoogle Scholar
• Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA 1992; 267: 1500–1502
   PubMedGoogle Scholar
• Hasegawa Y, Shimokata K, Ichiyama S, Saito H. Constrictive bronchiolitis obliterans and paraneoplastic pemphigus. Eur Respir J 1999; 13: 934–937
   PubMedGoogle Scholar
• Hoffman MA, Qiao X, Anhalt GJ. CD8+T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman's disease. N Engl J Med 2003; 349: 407–408
   PubMedGoogle Scholar
• Hertzberg MS, Schifter M, Sullivan J, Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: Significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63: 105–106
   Web of Science ®Google Scholar
• Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997; 12: 77–96
   PubMedGoogle Scholar
• Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999; 40: 750–754
   PubMedGoogle Scholar
• Izaki S, Yoshizawa Y, Kitamura K, Kato H, Hashimoto H, Korman NJ, et al. Paraneoplastic pemphigus: Potential therapeutic effect of plasmapheresis. Br J Dermatol 1996; 134: 987–989
   PubMedGoogle Scholar
• Rossum MM, Verhaegen NT, Jonkman MF, Mackenzie MA, Koster A, Van Der Valk PG, et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: Case report with review of novel treatment modalities. Leuk Lymphoma 2004; 45: 2327–2332
   PubMed Web of Science ®Google Scholar
• Hohwy T, Bang K, Steiniche T, Peterslund NA, d'Amore F. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur J Haematol 2004; 73: 206–209
   PubMed Web of Science ®Google Scholar
• Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679–690
   PubMed Web of Science ®Google Scholar
• Wang L, Bu D, Yang Y, Chen X, Zhu X. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 2004; 363: 525–531
   PubMed Web of Science ®Google Scholar
• Grando SA. New approaches to the treatment of pemphigus. J Investig Dermatol Symp Proc 2004; 9: 84–91
   PubMedGoogle Scholar
• Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 2004; 140: 327–334
   PubMed Web of Science ®Google Scholar
• Zhang B, Zheng R, Wang J, Bu D, Zhu X. Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. J Invest Dermatol 2006; 126: 832–840
   PubMedGoogle Scholar
• Chan LS. Epitope spreading in paraneoplastic pemphigus: Autoimmune induction in antibody-mediated blistering skin diseases. Arch Dermatol 2000; 136: 663–664
   PubMedGoogle Scholar
• Gloghini A, Colombatti A, Bressan G, Carbone A. Basement membrane components in lymphoid follicles: Immunohistochemical demonstration and relationship to the follicular dendritic cell network. Hum Pathol 1989; 20: 1001–1007
   PubMedGoogle Scholar
• Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66: 5527–5536
   PubMed Web of Science ®Google Scholar
• Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993; 14: 203–208
   PubMedGoogle Scholar
• Tuohy VK, Fritz RB, Ben-Nun A. Self-determinants in autoimmune demyelinating disease: Changes in T-cell response specificity. Curr Opin Immunol 1994; 6: 887–891
   PubMedGoogle Scholar
• Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, et al. Epitope spreading: Lessons from autoimmune skin diseases. J Invest Dermatol 1998; 110: 103–109
   PubMed Web of Science ®Google Scholar
• Stingl G, Holubar K. Coexistence of lichen planus and bullous pemphigoid: A immunopathological study. Br J Dermatol 1975; 93: 313–320
   PubMed Web of Science ®Google Scholar
• Stevens SR, Griffiths CE, Anhalt GJ, Cooper KD. Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Arch Dermatol 1993; 129: 866–869
   PubMedGoogle Scholar
• Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res 2003 Apr; 295(Suppl 1)S2–S11, Epub 2003 Jan 9
   PubMedGoogle Scholar
• DiColandrea T, Karashima T, Maatta A, Watt FM. Subcellular distribution of envoplakin and periplakin: Insights into their role as precursors of the epidermal cornified envelope. J Cell Biol 2000; 151: 573–586
   PubMedGoogle Scholar
• Amagai M, . Pemphigus. Dermatology, JL Bolognia, JL Jorizzo, RP Rapini, TD Horn, JM Mascaro, SH Saurat, et al. Mosby, London 2003; Volume 1: 449–462
   Google Scholar
• Lernmark A. Immune surveillance: Paraneoplastic or environmental triggers of autoimmunity. Crit Rev Immunol 1997; 17: 437–447
   PubMedGoogle Scholar
• Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190: 1717–1722
   PubMed Web of Science ®Google Scholar
• Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999; 45: 162–167
   PubMed Web of Science ®Google Scholar
• Chow S, Rizzo C, Ravitskiy L, Sinha AA. The role of T cells in cutaneous autoimmune disease. Autoimmunity 2005; 38: 303–317
   PubMed Web of Science ®Google Scholar
• De Panfilis G. Alterations in molecular killing mechanisms: Implications in skin disease. Br J Dermatol 2001; 145: 868–876
   PubMedGoogle Scholar
• Santamaria P. Effector lymphocytes in autoimmunity. Curr Opin Immunol 2001; 13: 663–669
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+T cells. J Exp Med 2003; 198: 569–580
   PubMed Web of Science ®Google Scholar
• Ulanet DB, Torbenson M, Dang CV, Casciola-Rosen L, Rosen A. Unique conformation of cancer autoantigen B23 in hepatoma: A mechanism for specificity in the autoimmune response. Proc Natl Acad Sci USA 2003 Oct 14; 100: 12361–12366, Epub 2003 Sep 30
   PubMedGoogle Scholar
• Wehrli P, Viard I, Bullani R, Tschopp J, French LE. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000; 115: 141–148
   PubMed Web of Science ®Google Scholar
• Langley RG, Walsh N, Nevill T, Thomas L, Rowden G. Apoptosis is the mode of keratinocyte death in cutaneous graft-versus-host disease. J Am Acad Dermatol 1996; 35: 187–190
   PubMedGoogle Scholar
• Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–493
   PubMed Web of Science ®Google Scholar
• Teraki Y, Shiohara T. Apoptosis and the skin. Eur J Dermatol 1999; 9: 413–425
   PubMedGoogle Scholar
• Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Boiko YYa, Senyuk OF. Autoreactive cytotoxic T lymphocytes in pemphigus and pemphigoid. Autoimmunity 1989; 3: 247–260
   PubMed Web of Science ®Google Scholar
• Grando SA, Vasilyev AN, Kostromin AP. Pemphigus antibodies and shedding snake serum enhance susceptibility of epidermal keratinocytes in natural cytotoxic reactions. Autoimmunity 1990; 8: 9–16
   PubMed Web of Science ®Google Scholar
• Koch WM, Richtsmeier WJ. Lysis of squamous cell carcinoma via antibody-dependent cellular cytotoxicity. Arch Otolaryngol Head Neck Surg 1989; 115: 669–676
   PubMedGoogle Scholar
• Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF. Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease. J Invest Dermatol 1996; 107: 377–383
   PubMedGoogle Scholar
• Friedmann PS, Strickland I, Pirmohamed M, Park BK. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598–604
   PubMed Web of Science ®Google Scholar
• Santos GW. Syngeneic or autologous graft-versus-host disease. Int J Cell Cloning 1989; 7: 92–99
   PubMedGoogle Scholar
• Daoud MS, Pittelkow MR. Lichen planus. Fitzpatrick's dermatology in general medicine6th ed., IM Freedberg, AZ Eisen, K Wolff, KF Austen, LA Goldsmith, SI Katz. McGraw-Hill, New York, NY 2003; Volume 1: 463–478
   Google Scholar
• Liu CC, Young LH, Young JD. Lymphocyte-mediated cytolysis and disease. N Engl J Med 1996; 335: 1651–1659
   PubMed Web of Science ®Google Scholar
• Garban HJ, Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol Oncol 1999; 73: 257–264
   PubMedGoogle Scholar
• Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645–2656
   PubMed Web of Science ®Google Scholar
• Barrett A, Jiang YZ. Immune responses to chronic myeloid leukaemia. Bone Marrow Transplant 1992; 9: 305–311
   PubMed Web of Science ®Google Scholar
• Iho S, Shau H, Golub SH. IL-6 enhances the cytotoxic activity of thymocyte-derived CD56+ cells. Cell Immunol 1992; 144: 1–10
   PubMedGoogle Scholar
• Nakashima M, Watanabe T, Koprowski H, Schuchter L, Steplewski Z. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes. Cell Immunol 1994; 155: 53–61
   PubMedGoogle Scholar
• Nousari HC, Kimyai-Asadi A, Anhalt GJ. Elevated serum levels of interleukin-6 in paraneoplastic pemphigus. J Invest Dermatol 1999; 112: 396–398
   PubMedGoogle Scholar
• Martel P, Loiseau P, Joly P, Busson M, Lepage V, Mouquet H, et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun 2003; 20: 91–95
   PubMedGoogle Scholar
• Voltz R. Paraneoplastic neurological syndromes: An update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002; 1: 294–305
   PubMed Web of Science ®Google Scholar
• Tanaka M, Tanaka K, Shinozawa K, Idezuka J, Tsuji S. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1998; 161: 88–90
   PubMed Web of Science ®Google Scholar
• Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47: 9–17
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S, et al. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 2003 Oct; 52: 632–637, Epub 2003 Jun 21
   PubMed Web of Science ®Google Scholar
• Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4: 1321–1324
   PubMed Web of Science ®Google Scholar
• Tanaka K. A study on pathomechanisms of paraneoplastic neurological syndrome [Japanese]. Rinsho Shinkeigaku 2001; 41: 1150–1152
   PubMedGoogle Scholar
• Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001; 117: 326–332
   PubMed Web of Science ®Google Scholar
• Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 2001; 117: 1464–1470
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003 Jul 8; 100: 8372–8377, Epub 2003 Jun 25
   PubMed Web of Science ®Google Scholar
• Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003; 121: 550–556
   Google Scholar
• Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-lived CD4+ and CD8+T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001; 50: 64–72
   PubMed Web of Science ®Google Scholar
• Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, et al. Thymomas alter the T-cell subset composition in the blood: A potential mechanism for thymoma-associated autoimmune disease. Blood 2000; 96: 3872–3879
   PubMed Web of Science ®Google Scholar